Fig. 1
From: Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury
Panx1-targeting nanobodies show cross-reactive binding to murine and human Panx1. a Flow cytometry analysis of the binding of Panx1-targeting nanobodies (Nb1, Nb3 and Nb9) and non-targeting Nb (1000 nM) to DUBCA wild-type (WT) cells and DUBCA cells overexpressing mouse Panx1 (mPanx1) or human Panx1 (hPanx1). Representative data of 3 independent experiments is shown. b Flow cytometry analysis of the binding of different concentrations of Panx1-targeting nanobodies (Nb1, Nb3 and Nb9) (0–600 nM) to DUBCA mPanx1 and hPanx1 cells. Binding values for Nb1 (orange), Nb3 (blue) and Nb9 (green) were plotted to define affinity towards mPanx1 and hPanx1 (n = 3 independent experiments). Data were expressed as means